Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 23%
Buy 8%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health has demonstrated strong growth potential, evidenced by a remarkable 70% year-over-year increase in subscribers in the fourth quarter and an expanding international portfolio that contributes to incremental revenue. The company is strategically positioned to capitalize on emerging weight-loss opportunities, particularly through partnerships that may enhance revenue contributions from new weight-loss drugs like CagriSema and Amycretin, which are currently in trials. Additionally, the diversification of its offerings beyond just weight loss, including ongoing growth in specialties like sexual health, mitigates concentration risk and supports the company's overall financial resilience and growth trajectory.

Bears say

Hims & Hers Health is experiencing a significant slowdown in revenue growth, as evidenced by disappointing fourth quarter 2025 earnings results and weak guidance for the first quarter of 2026. Full-year 2026 revenue expectations have been downgraded to between $2.7 billion and $2.9 billion, significantly lower than prior estimates and reflecting a decline in projected revenue and EBITDA figures for fiscal year 2027. Additionally, the company faces increasing legal and regulatory risks, further compounding concerns about its future financial performance.

HIMS has been analyzed by 13 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 8% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 13 analysts, HIMS has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.